Alvotech (ALVO) vs Novavax (NVAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Novavax (NVAX) has outperformed Alvotech (ALVO) over the past year, gaining 23.7% versus a loss of 34.7%. Alvotech is the larger company by market cap ($2.02 billion vs $1.82 billion), about 1.1 times the size, while Novavax is growing revenue faster (+64.7% vs +19.7%). Novavax converts more of its revenue into profit, with a net margin of 39.2% versus 4.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALVO | NVAX |
|---|---|---|
| Share price | $5.67 | $11.01 |
| Market cap | $2.02B | $1.82B |
| 1-day change | -3.08% | -1.87% |
| YTD return | +10.53% | +63.84% |
| 1-year return | -34.68% | +23.71% |
| 5-year return | — | -93.20% |
| Forward P/E | 24.83 | — |
| EPS (TTM) | $-0.62 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $586.32M | $1.12B |
| Revenue growth (YoY) | +19.74% | +64.69% |
| Net income (latest FY) | $27.92M | $440.30M |
| Gross margin | 59.82% | 93.50% |
| Operating margin | 13.34% | 40.30% |
| Net margin | 4.76% | 39.19% |
| 52-week high | $9.05 | $13.39 |
| 52-week low | $2.94 | $6.20 |
| Distance from 52-week high | -37.31% | -17.77% |
| Analyst consensus | none | buy |
| Avg. price target upside | +19.93% | +27.16% |
| Average volume | 1.05M | 5.21M |
| Shares outstanding | 356.82M | 164.95M |
| Employees | 1,279 | 749 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVAX has outperformed ALVO by 58.4 percentage points over the past year.
- Novavax is more profitable, keeping 39.2 cents of every revenue dollar as net income versus 4.8 cents for Alvotech.
- Novavax grew revenue faster in its latest fiscal year (+64.69% vs +19.74%).
About Alvotech
ALVO stock →Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,279 employees
About Novavax
NVAX stock →Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees
ALVO vs NVAX FAQ
Which is bigger, Alvotech or Novavax?
Alvotech (ALVO) is larger, with a market capitalization of $2.02B compared with $1.82B for Novavax (NVAX).
Which stock has performed better over the past year, ALVO or NVAX?
NVAX returned +23.71% over the past 12 months, compared with -34.68% for ALVO (price return, excluding dividends). Past performance does not predict future results.
Are Alvotech and Novavax in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.